132 related articles for article (PubMed ID: 8306496)
41. Migration inhibition factor secreting human T-cell lines reactive to PPD: a study of their antigen specificity, MHC restriction and the use of Epstein-Barr virus-transformed B-cell lines as requirement for antigen-presenting cells.
Vyakarnam A; Lachmann PJ
Immunology; 1984 Dec; 53(4):601-10. PubMed ID: 6209204
[TBL] [Abstract][Full Text] [Related]
42. Isolation and characterization of human antigen-specific B lymphocytes.
Oshiba A; Renz H; Yata J; Gelfand EW
Clin Immunol Immunopathol; 1994 Sep; 72(3):342-9. PubMed ID: 7520374
[TBL] [Abstract][Full Text] [Related]
43. Epstein-Barr virus-transformed B cells process and present Mycobacterium tuberculosis particulate antigens to T-cell clones.
Lombardi G; del Gallo F; Vismara D; Piccolella E; de Martino C; Garzelli C; Puglisi C; Colizzi V
Cell Immunol; 1987 Jul; 107(2):281-92. PubMed ID: 3036374
[TBL] [Abstract][Full Text] [Related]
44. Human self-reactive T cell clones expressing identical T cell receptor beta chains differ in their ability to recognize a cryptic self-epitope.
Quaratino S; Feldmann M; Dayan CM; Acuto O; Londei M
J Exp Med; 1996 Feb; 183(2):349-58. PubMed ID: 8627148
[TBL] [Abstract][Full Text] [Related]
45. Expression of mucin (MUC-1) from a mini-Epstein-Barr virus in immortalized B-cells to generate tumor antigen specific cytotoxic T cells.
Kilger E; Pecher G; Schwenk A; Hammerschmidt W
J Gene Med; 1999; 1(2):84-92. PubMed ID: 10738572
[TBL] [Abstract][Full Text] [Related]
46. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
Hill AB; Lee SP; Haurum JS; Murray N; Yao QY; Rowe M; Signoret N; Rickinson AB; McMichael AJ
J Exp Med; 1995 Jun; 181(6):2221-8. PubMed ID: 7539044
[TBL] [Abstract][Full Text] [Related]
47. Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants.
Simitsek PD; Campbell DG; Lanzavecchia A; Fairweather N; Watts C
J Exp Med; 1995 Jun; 181(6):1957-63. PubMed ID: 7539034
[TBL] [Abstract][Full Text] [Related]
48. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation.
Malcherek G; Wirblich C; Willcox N; Rammensee HG; Trowsdale J; Melms A
Eur J Immunol; 1998 May; 28(5):1524-33. PubMed ID: 9603457
[TBL] [Abstract][Full Text] [Related]
49. Heat shock increases antigenic peptide generation but decreases antigen presentation.
Pépin E; Villiers CL; Gabert FM; Serra VA; Marche PN; Colomb MG
Eur J Immunol; 1996 Dec; 26(12):2939-43. PubMed ID: 8977289
[TBL] [Abstract][Full Text] [Related]
50. An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation.
Manoury B; Hewitt EW; Morrice N; Dando PM; Barrett AJ; Watts C
Nature; 1998 Dec; 396(6712):695-9. PubMed ID: 9872320
[TBL] [Abstract][Full Text] [Related]
51. Mechanisms of the failure of resting B cells to present tetanus toxoid antigen to T cells.
Brozek C; Umetsu D; Schneeberger E; Geha RS
J Immunol; 1984 Mar; 132(3):1144-50. PubMed ID: 6607279
[TBL] [Abstract][Full Text] [Related]
52. Immunization with meningococcal polysaccharide-tetanus toxoid conjugate induces polysaccharide-reactive T cells in mice.
Muthukkumar S; Stein KE
Vaccine; 2004 Mar; 22(9-10):1290-9. PubMed ID: 15003659
[TBL] [Abstract][Full Text] [Related]
53. In vitro T cell responses to a candidate Epstein-Barr virus vaccine: human CD4+ T cell clones specific for the major envelope glycoprotein gp340.
Ulaeto D; Wallace L; Morgan A; Morein B; Rickinson AB
Eur J Immunol; 1988 Nov; 18(11):1689-97. PubMed ID: 2904885
[TBL] [Abstract][Full Text] [Related]
54. Antigen presentation by common variable immunodeficiency (CVID) B cells and monocytes is unimpaired.
Thon V; Eggenbauer H; Wolf HM; Fischer MB; Litzman J; Lokaj J; Eibl MM
Clin Exp Immunol; 1997 Apr; 108(1):1-8. PubMed ID: 9097903
[TBL] [Abstract][Full Text] [Related]
55. Isolation and characterization of Ni-specific T cell clones from patients with Ni-contact dermatitis.
Sinigaglia F; Scheidegger D; Garotta G; Scheper R; Pletscher M; Lanzavecchia A
J Immunol; 1985 Dec; 135(6):3929-32. PubMed ID: 2415590
[TBL] [Abstract][Full Text] [Related]
56. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
57. Epstein-Barr virus-transformed B-cells as efficient antigen presenting cells to propagate Aspergillus-specific cytotoxic T-lymphocytes.
Ramadan G
Egypt J Immunol; 2008; 15(1):145-57. PubMed ID: 20306679
[TBL] [Abstract][Full Text] [Related]
58. Functional analysis of two tetanus toxin universal T cell epitopes in their interaction with DR1101 and DR1104 alleles.
Valmori D; Sabbatini A; Lanzavecchia A; Corradin G; Matricardi PM
J Immunol; 1994 Mar; 152(6):2921-9. PubMed ID: 7511633
[TBL] [Abstract][Full Text] [Related]
59. Activation of human B lymphocytes: frequency of antigen-specific B cells triggered by alloreactive or by antigen-specific T cell clones.
Lanzavecchia A; Parodi B; Celada F
Eur J Immunol; 1983 Sep; 13(9):733-8. PubMed ID: 6604634
[TBL] [Abstract][Full Text] [Related]
60. Capacity of antigen uptake by B cells, fibroblasts or macrophages determines efficiency of presentation of a soluble self antigen (C5) to T lymphocytes.
Stockinger B
Eur J Immunol; 1992 May; 22(5):1271-8. PubMed ID: 1577067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
